非典型脑膜瘤与复发性脑膜瘤的代谢谱分析:质子磁共振波谱的比较分析
该研究在琉球大学医院回顾性纳入2011至2021年93例脑膜瘤患者,比较WHO 1级与2/3级肿瘤的术前质子磁共振波谱代谢物比值。结果显示2/3级组谷氨酰胺、谷氨酸、脂质和胆碱的肌酸比值均显著升高,且与MIB-1标记指数升高相关;ROC分析提示谷氨酰胺曲线下面积最大(0.765),区分两组的截断值为5.76。
要点
- WHO 2/3级脑膜瘤的谷氨酰胺、谷氨酸、脂质和胆碱的肌酸比值均显著高于WHO 1级。
- 2/3级组平均MIB-1标记指数为8.58,显著高于1级组,提示与病理恶性度强相关。
- ROC分析中谷氨酰胺曲线下面积为0.765,区分两组的截断值为5.76。
核心结论
- 病理分级为WHO 2或3级的脑膜瘤中,谷氨酰胺、谷氨酸、脂质和胆碱等代谢产物显著增加,这些变化与MIB-1标记指数升高相关。
- 作者认为质子磁共振波谱可能有助于无创预测肿瘤代谢活性和肿瘤复发。
- 作者根据ROC分析认为谷氨酰胺可能是预测脑膜瘤未来生长及早期手术获益的潜在指标。
研究设计与样本
- 在琉球大学医院回顾性纳入2011年至2021年间诊断的93例脑膜瘤患者,纳入标准包括既往手术、脑膜瘤病理诊断及术前质子磁共振波谱检查。
- I组为71例WHO 1级脑膜瘤患者,II组为22例WHO 2或3级脑膜瘤患者(其中WHO 2级19例、WHO 3级3例)。
- 回顾性比较分析患者背景与肿瘤代谢物。
主要发现
- I组与II组在年龄和性别等人口学特征上无显著差异。
- 与I组相比,II组肿瘤切除程度显著更低(p < 0.01)、MIB-1标记指数更高(p < 0.05)、既往放疗史比例更高(p < 0.001)、肿瘤复发率更高(p = 0.005)。
- 质子磁共振波谱显示,除乳酸外,II组所有代谢物的肌酸比值中位数均显著高于I组:谷氨酰胺/肌酸为8.46、谷氨酸/肌酸为9.49、脂质/肌酸为11.36、胆碱/肌酸为2.77。
- ROC分析显示,10种代谢物中谷氨酰胺的曲线下面积最大,为0.765;区分I组与II组的截断值为5.76。
- II组平均MIB-1标记指数为8.58,显著高于I组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Meningiomas are predominantly benign, but some cases exhibit recurrent growth after surgery and undergo malignant transformation to WHO grade 2 or grade 3. Despite progress in genetic analyses, advancements in metabolomic analysis remain less established. Herein, the authors investigated metabolic activity differences between WHO grade 1 meningiomas and WHO grade 2 or 3 meningiomas by noninvasively using proton magnetic resonance spectroscopy (1H-MRS), aiming to preoperatively estimate malignancy. They also reviewed the literature to elucidate this aspect of meningioma research. METHODS: At Ryukyu University Hospital, the authors focused on 93 patients diagnosed with meningioma between 2011 and 2021. The inclusion criteria encompassed prior surgery, pathological diagnoses of meningioma, and preoperative 1H-MRS. Group I included 71 patients with WHO grade 1 meningioma and group II included 22 patients, comprising 19 and 3 with WHO grade 2 and 3 meningioma, respectively. The authors retrospectively conducted a comparative analysis of patient backgrounds and tumor metabolites. RESULTS: Group I and II did not differ significantly in terms of patient demographic characteristics (age and sex). Group II demonstrated a significantly lower extent of tumor resection (p < 0.01), higher MIB-1 labeling index (LI) (p < 0.05), higher incidence of prior irradiation (p < 0.001), and increased rate of tumor recurrence (p = 0.005) compared to group I. According to 1H-MRS, all metabolites, except lactate, displayed significantly higher median creatine (Cr) ratios in group II than group I: glutamine/Cr was 8.46, glutamate/Cr was 9.49, lipid/Cr was 11.36, and choline/Cr was 2.77. According to the receiver operating characteristic (ROC) analysis, glutamine had the largest area under the curve of 0.765 among 10 metabolites, and the cutoff value for distinguishing between group I and II was 5.76. CONCLUSIONS: In cases pathologically graded as WHO grade 2 or 3 meningiomas, metabolic products such as glutamine, glutamate, lipids, and choline increased significantly. These changes were correlated with elevation of the MIB-1 LI. In group II, the mean MIB-1 LI was 8.58, significantly higher than in group I, suggesting a strong association with pathological malignancy. Therefore, 1H-MRS may help to noninvasively predict tumor metabolic activity and tumor recurrence. Furthermore, the authors concluded from the ROC analysis that glutamine may be a potential indicator of future growth of meningioma and benefits of early surgery.
引用
- Kuninaka T, Kisyaba K, Kobayashi S, et al. Metabolic profiling of atypical meningioma and recurrent meningioma: a comparative analysis with proton magnetic resonance spectroscopy. J Neurosurg. 2024. PMID: 39151200. doi:10.3171/2024.4.JNS24187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。